

CSD/BSE&NSE/CC/2024-25

February 9, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Revised Schedule of Conference Call for Investors

.....

With reference to our intimation dated February 06, 2025, please find enclosed revised intimation regarding the schedule of conference call for investors on **Wednesday, February 12, 2025 at 07.30 p.m. IST to discuss the Un-audited Financial Results for the Q3 & 9M FY25**, to be considered on February 12, 2025.

This is for your information and record.

Thanking You.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Encl: as above

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor,
819-821, Andheri Kurla Road, Chakala, Andheri East,
Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers,
Plot No.1, Hyderabad Knowledge City, TSIC,
Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



Suven Pharmaceuticals Ltd to host Q3 & 9MFY25 Results Conference call on Wednesday, February 12, 2025 @ 7.30 pm

Suven Pharmaceuticals Ltd will conduct a conference call to discuss its Q3 & 9MFY25 results performance. The management team will be represented by Mr. Vivek Sharma (Executive Chairman), Dr. V Prasada Raju (Managing Director), Dr. Sudhir Kumar Singh (Chief Executive Officer), Mr. Himanshu Agarwal (Chief Financial Officer) & Cyndrella Carvalho (Head – IR).

The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As. The financial results will be announced earlier on February 12, 2025.

In order to pre-register: Copy this URL in your browser:

<https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=2820130&linkSecurityString=134300f00e>

Details of the conference call are as follows:

Timing	7.30 pm IST on Wednesday, February 12, 2025
<hr/>	
Conference dial-in	
Primary number	+91 22 6280 1141/+91 22 7115 8042
Singapore Toll Free Number	800 101 2045
Hong Kong Toll Free Number	800 964 448
USA Toll Free Number	1 866 746 2133
UK Toll Free Number	0 808 101 1573

- ENDS -

For further information please contact

Cyndrella Carvalho, (Head – Investor Relations)
Suven Pharmaceuticals Limited
Tel: +91 40 2354 9414
Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar
CDR India
Tel: +91 98206 37649 / 77770 35061
Email: gavin@cdr-india.com
rishab@cdr-india.com